Autologous bone marrow transplant for the treatment of patients who have experienced heart failure

Mundy L, Hiller JE
Record ID 32006001401
Authors' results and conclusions: There are a number of good quality studies included in this summary which described the use of bone marrow cells for autologous transplantation for patients who have experienced a myocardial infarction. Significant improvements were reported by some studies in surrogate outcomes, such as left ventricular ejection fraction, at short-term follow-up. These results were conflicted by another study which reported no significant improvement. Long-term follow-up may indicate that no benefit is afforded to patients who have undergone bone marrow transplant. Most authors agree that more work needs to be undertaken to ascertain the optimal cell type to be used for transplantation, how many cells to use and the timing of cell transfer. In addition studies need to present long-term follow-up data.
Authors' recomendations: Despite the lack of long-term follow-up data, HealthPACT are of the opinion that this technology is likely to enter the Australian health system soon and therefore recommended a horizon scanning report.
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Myocardium
  • Neovascularization, Physiologic
  • Bone Marrow Transplantation
  • Heart Diseases
  • Heart Failure
  • Regeneration
  • Transplantation, Autologous
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.